drugset / Trial / NCT06430437
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations
Timeline
- Start
- 2024-07-29
- Primary completion
- 2026-02
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-A1811 | Monoclonal antibody | — | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |
| Comparator | Pemetrexed | Small molecule | — | Intravenous |